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Research
AbstrACt
Objectives To (1) explore the clustering of community 
pharmacies in England and (2) determine the relationship 
between community pharmacy clustering, urbanity and 
deprivation.
Design An area-level analysis spatial study.
setting England.
Primary and secondary outcome measures Community 
pharmacy clustering determined as a community 
pharmacy located within 10 min walking distance to 
another community pharmacy.
Participants Addresses and postal codes of each 
community pharmacy in England were used in the 
analysis. Each pharmacy postal code was assigned to a 
lower layer super output area, which was then matched 
to urbanity (urban, town and fringe or village, hamlet and 
isolated dwellings) and deprivation decile (using the Index 
of Multiple Deprivation score).
results 75% of community pharmacies in England were 
located in a ‘cluster’ (within 10 min walking distance of 
another pharmacy): 19% of community pharmacies were 
in a cluster of two, while 56% of community pharmacies 
were in clusters of three or more. There was a linear 
relationship between community pharmacy clustering 
and social deprivation—with clustering more prevalent 
in areas of higher deprivation: for community pharmacies 
located in areas of lowest deprivation (decile 1), there 
was a significantly lower risk of clustering compared 
with community pharmacies located in areas of highest 
deprivation (relative risk 0.12 (95% CI 0.10 to 0.16)).
Conclusions Clustering of community pharmacies in 
England is common, although there is a positive trend 
between community pharmacy clustering and social 
deprivation, whereby clustering is more significant in areas 
of high deprivation. Arrangements for future community 
pharmacy funding should not solely focus on distance from 
one pharmacy to another as means of determining funding 
allocation, as this could penalise community pharmacies 
in our most deprived communities, and potentially have 
a negative effect on other healthcare providers, such as 
general practitioner and accident and emergency services. 
IntrODuCtIOn 
In recent years, community pharmacies have 
emerged as strategically important settings, 
which play a crucial role in delivering 
healthcare and public health services.1 In 
the UK, for example, community pharma-
cies offer a range of tiered services: the first 
level of service, the essential service, includes 
dispensing medication and providing 
medication-related advice; the second, the 
advanced service, allows pharmacists, among 
other things, to provide influenza vaccina-
tions and medicines use reviews; the third, 
the locally commissioned services are used 
to address the needs of the local popula-
tion and can include smoking cessation, and 
minor illness schemes.2 Importantly, through 
these patient-focused roles, community phar-
macy services are able to manage people 
with minor illnesses and some long-term 
conditions. This is advantageous, as people 
with minor illness can be directed away from 
other healthcare providers, such as general 
practitioners (GPs) and accident and emer-
gency (A&E) departments.3 4 This approach, 
therefore, has the potential to free up valu-
able healthcare resource, which allows other 
primary and secondary care services to mange 
people with more serious conditions where 
community pharmacy involvement would not 
be appropriate.
Indeed, with the average waiting times 
for a non-urgent GP appointment around 
13 days, and the number of people waiting 
longer than 4 hours in A&E departments 
strengths and limitations of this study
 ► This is the first study exploring community pharma-
cy clustering, and how this varies according to social 
deprivation and urbanity.
 ► We conceptualised a community pharmacy cluster 
using a 0.5-mile straight line which is a limitation 
of the work.
 ► We did not model what would happen to community 
pharmacy access if the clusters were removed due 
to community pharmacy closures.
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increasing, it is clear UK healthcare services are under 
unprecedented strain.5 Furthermore, it is known that 
people living in areas of higher socioeconomic depri-
vation are more likely to need primary and secondary 
health services, but that provision is in fact lower in these 
high-need neighbourhoods: the inverse care law.6 The 
problem of timely access to healthcare services is therefore 
adversely affecting people in the most deprived commu-
nities—potentially further widening health inequalities 
and thereby putting even more pressure on healthcare 
services in the longer term. Previous work has shown that, 
in contrast to the inverse care law for GPs and hospital 
services, a positive pharmacy care law exists—whereby 
people living in areas of highest deprivation have better 
access to community pharmacies.7 It is also known that 
the urbanity of an area is an important consideration for 
healthcare access, with people from urban areas living in 
greater proximity to GP services, when compared with 
people living in rural areas.8 Community pharmacies, 
therefore, have the potential to reach people in the areas 
of greatest need thereby offering additional healthcare 
access in areas that are traditionally ‘underdoctored’—
including rural areas.8
Despite the significant—and perhaps underused—
potential of community pharmacies, austerity has seen 
the implementation of UK government funding cuts to 
the English community pharmacy sector—with some 
estimates suggesting one in four community phar-
macies could close as a result of the reduced funding 
envelope.9 It has been argued that because community 
pharmacies cluster together, some can be cut without 
impacting on service provision. In a letter to the Phar-
maceutical Services Negotiating Committee (the body 
that represents National Health Service (NHS) phar-
macy contractors in England), the Department of 
Health state that ‘40% of pharmacies are in a cluster 
where there are three or more pharmacies within 10 min 
walk’ and that ‘in some parts of the country there are 
more pharmacies than are necessary to maintain good 
access’.10 Despite these claims, and the potential impact 
on funding allocations and therefore service provi-
sion, there are no published studies that explore the 
clustering of community pharmacies in England, and 
how such clustering is linked to socioeconomic depri-
vation and urbanity. The research, therefore, aimed to: 
(1) explore the clustering of community pharmacies in 
England by 10 min walking distance and (2) determine 
the relationship between community pharmacy clus-
tering, urbanity and deprivation.
MethODs
Design
This study used geographical information systems to 
explore community pharmacy clustering according to 
urbanity and deprivation. For the purposes of the study, 
a community pharmacy was defined as a premises regis-
tered with the General Pharmaceutical Council for the 
purposes of compounding, procurement, storage and 
distribution of medicines and appliances11; we excluded 
premises that were solely registered as internet pharma-
cies in the analysis.
Data and variables
Community pharmacy data were obtained from the 
Geo-Healthcare Access Database.12 This open access 
database contains data on the address and postal code 
of each community pharmacy premises in England 
(matched to their corresponding coordinates using the 
Office of National Statistics postcode directory, 2014); 
the last update of the dataset was in 2016. Community 
pharmacy locations were mapped and their corre-
sponding 2011 lower layer super output areas (LSOAs) 
were extracted. There are 32 844 LSOAs in England 
and these geographical areas comprise approximately 
1–3000 people living in 400–1200 households, and were 
designed to improve the reporting of small area statis-
tics. Urbanity is also a factor in access to healthcare 
services including community pharmacies so, using 
the rural–urban classification (2011) each community 
pharmacy LSOA was assigned to one of three catego-
ries: (1) urban, (2) town or fringe or (3) village, hamlet 
and isolated dwellings. These categories were aggre-
gated from the original rural–urban classification which 
assigns areas to one of six rural or four urban settlement/
context types. The 2015 Index of Multiple Deprivation 
(IMD) score was also matched to each community phar-
macy’s LSOA (from the Office of National Statistics). 
The IMD is an overall measure of multiple deprivation 
experienced by people living in an area, and comprises 
37 separate indicators organised across seven domains 
of deprivation (income, employment, health and 
disability, education, skills and training, crime, barriers 
to housing and services and living environment) which 
are combined, using appropriate weights.13
Data analysis
Locations of community pharmacies in England were 
mapped using ArcMap (V.10.3) and 0.5-mile (straight-
line) buffers were placed around the site to represent a 
10 min walk, using an average walking speed of 3 mph 
(4 km).14 The number of community pharmacies which 
were isolated or clustered in groups of two, or three or 
more were then extracted for all locations. A cluster was 
defined if the buffer around a single community phar-
macy contained two or more unique sites. The number 
of community pharmacies within each individual buffer 
was then calculated and summarised. In addition to 
examining data for all community pharmacies, further 
breakdown of clustering took place depending on 
whether or not the LSOA of the pharmacy was ‘urban’, 
‘town or fringe’ or ‘village, hamlet and isolated dwell-
ings’. This process was repeated for all deprivation 
deciles based on the IMD 2015 for England, whereby 
the most deprived decile (decile 10) equated to the 
most deprived 10% of LSOAs, while the least deprived 
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decile (decile 1) represented the 10% least deprived 
LSOAs (figure 1). The relative risk for community 
pharmacy clustering by deprivation was then calculated 
according to deprivation decile. For the deprivation 
analysis, a community pharmacy ‘cluster’ was consid-
ered as three or more community pharmacies within a 
10 min walking distance of each other.
Patient and public involvement
As this study involved secondary data analysis from the 
Geo-Healthcare Access Database, patients or the public 
were not involved in the design or delivery of this research.
results
Overall, our results show that the percentage of community 
pharmacies within 10 min walking distance (0.5 mile) of one 
another is 75%: 19% of community pharmacies were in a 
cluster of two, while 56% of community pharmacies were in 
clusters of three or more. An example of community phar-
macy clustering is shown visually in figure 2.
Clustering of community pharmacies by urban–rural 
classification
For community pharmacies located in urban areas 
(n=10 438), there was no clustering for 19% of community 
Figure 1 Map of England with LSOAs stratified according to deprivation. IMD, Index of Multiple Deprivation; LSOAs, lower 
layer super output areas.
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pharmacies, 19% were located in a cluster of two, while 
62% were located in clusters of three or more. In town 
and fringe areas (n=1147), there was no clustering in 94% 
of community pharmacies, 5% were located in clusters of 
two, while 1% were located in clusters of three or more. 
In village areas (n=153), there was no clustering in 94% of 
community pharmacies, 4% were located in clusters of two, 
while 2% were located in clusters of three or more.
Clustering of community pharmacies by IMD
When stratifying by IMD, there was, overall, a linear 
relationship between community pharmacy clustering 
and social deprivation—with clustering more prevalent 
in areas of higher deprivation (figure 3); the highest 
percentage of community pharmacy clustering was 
62%, observed in deprivation decile 10, while the lowest 
percentage of community pharmacy clustering was 8%, 
Figure 2 An example of community pharmacy distribution in England, showing: no clustering (blue circle), clusters of 2 (yellow 
circle) and clusters of 3 or more (green circle).
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observed in deprivation decile 1 (figure 4). Community 
pharmacies located in the most deprived areas were 
significantly more likely to exist as clusters: for commu-
nity pharmacy clusters of three or more, there was a 
significantly higher risk of clustering in deprivation 
decile 10, compared with all the other deciles. When 
comparing community pharmacies in decile one (least 
deprived) to community pharmacies in decile 10 (most 
deprived), there was an 88% lower risk of clustering 
for community pharmacies in the least deprived areas 
(table 1).
DIsCussIOn
The key findings of the study show that clustering of commu-
nity pharmacies in England is common—with around 56% 
of all community pharmacies existing in a cluster of three 
or more. There is also a positive trend between deprivation 
and community pharmacy clustering, whereby clustering 
is significantly more common in areas of high depriva-
tion. Clustering of community pharmacies was also more 
common in urban areas, when compared to rural areas. 
These findings may well reflect both health need and popu-
lation size in the respective neighbourhoods.
This is the first study that has empirically explored 
whether community pharmacies are clustered in 
England—and how such clustering varies according 
to deprivation and urbanity. Previous literature has 
shown that geographical proximity of services can be an 
important consideration for healthcare utilisation; for 
example, Turnbull et al showed that call rates to primary 
care centres decreased with increasing distance. The 
same study also showed that higher call rates were asso-
ciated with more deprived areas.15 Furthermore, Lin et al 
who examined travel distance to hospital and the asso-
ciated effect on hospitalisations in Canada, showed that 
admission rates were inversely proportional to hospital 
distance.16 It has also been shown in the literature that 
proximity to healthcare services is an important consider-
ation for healthcare utilisation, and is an important factor 
Figure 3 Map of the Northeast of England showing; (A) ordinance survey map; (B) deprivation by LSOA and, (C) community 
pharmacy clustering. IMD, Index of Multiple Deprivation; LSOAs, lower layer super output areas. 
Figure 4 Percentage clustering of community pharmacies 
in England according to social deprivation (1 is the least 
deprived, while 10 is the most deprived).
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for health outcome. For example, a study by Okwaraji 
et al showed that, in a remote area of rural Ethiopia, the 
distance to the nearest health centre had a significant 
effect on child mortality—with children living greater 
than 1.5 hours walk from the health centre having a two 
to three greater risk of death compared with children 
who live within 1.5 hours walk.17 Clearly the context of 
this work is different to healthcare settings in England, 
so limited comparisons can be drawn. However, given 
the well-established relationship between health and 
place, it would be prudent for future research to explore 
how community pharmacy distribution is associated with 
health of a particular area. The literature has also shown 
that healthcare access, from a geographical perspec-
tive, tends to be lower among rural communities when 
compared to urban communities. For example, Lovett 
et al, who explored GP accessibility by car travel and public 
transport, showed examples of rural areas in East Anglia 
(typically with low levels of personal mobility and high 
health need) where there was no daytime bus services or 
no community transport, which allowed travel/access to 
a GP.18 These challenges have been summarised by Baird 
and Wright, who coined the term ‘rural health depriva-
tion’, and argue that, to improve the health of the nation, 
more needs to be done to develop care pathways for rural 
communities.19 Although we have not measured accessi-
bility of community pharmacy by population, our find-
ings that community pharmacy clustering is lower in rural 
areas lend support to the hypothesis that accessibility to 
healthcare is lower among rural communities.
In terms of study limitations, while we believe our 
results are robust, and have important policy implica-
tions for the way in which community pharmacies are 
funded, we acknowledge there are several: first, we recog-
nise that a 10 min walk (0.5 mile) from each community 
pharmacy was represented using a straight-line distance 
from the central point of each community pharmacy’s 
postal code to create a buffer. This assumes people are 
able to walk in any direction from that postal code and 
always in a straight line, while, in reality, people are 
often constrained to pathways that curve, or are cut-off 
by barriers (such as lakes, train tracks or busy roads). 
We also acknowledge that we did not consider commu-
nity pharmacy utilisation in our analysis; just because 
a community pharmacy is located in a particular area, 
does not necessarily mean people from that area choose 
to use it. In addition, we did not consider which types 
of service were being used from the community phar-
macies; it is possible that service utilisation will change 
according to health need of the population (eg, people 
living in areas with a high prevalence of smoking might 
use more community pharmacy smoking cessation 
services). We also acknowledge that we did not explore 
how community pharmacy clustering varied according 
to population type; for example, it is possible that some 
community pharmacies serve different types of popula-
tions, such as black and minority ethnic groups or older 
populations. It would be prudent, therefore, that future 
work establishes the types of people that use community 
pharmacies services, and how this varies according to 
urbanity, deprivation and local health need.
The policy implications of this work are clear: cutting 
the funding of community pharmacies by clustering will 
disproportionately affect community pharmacies located 
in the most deprived communities: potentially leading 
to an inverse pharmacy care law. Given that community 
pharmacies provide effective public health services,20 
this has the potential to further widen health inequali-
ties—should community pharmacies in these areas close. 
Indeed, it would undermine the department of health’s 
responsibilities to reduce inequalities in access to NHS 
services. There have been recent reports of some large 
community pharmacy organisations taking the decision 
to close some of their community pharmacies as they 
have become ‘commercially unviable’, although it is not 
yet clear what areas will be affected.21 We note that the 
department of health has introduced a Pharmacy Access 
Scheme (PhAS), whereby, according to specific criteria, 
Table 1 Relative risk (RR) of community pharmacy clustering according to deprivation decile (1 is the least deprived, while 10 
is the most deprived)
Deprivation decile
No clustering Clustering of 2 Clustering of ≥3
RR (95% CI) RR (95% CI) RR (95% CI)
1 3.38 (3.06 to 3.72) 1.20 (1.01 to 1.43) 0.12 (0.10 to 0.16)
2 3.08 (2.78 to 3.39) 1.06 (0.89 to 1.26) 0.27 (0.23 to 0.31)
3 2.78 (3.51 to 3.08) 1.28 (1.09 to 1.49) 0.31 (0.27 to 0.35)
4 2.52 (2.27 to 2.80) 1.49 (1.29 to 1.72) 0.34 (0.30 to 0.38)
5 2.48 (2.23 to 2.74) 1.40 (1.21 to 1.62) 0.38 (0.34 to 0.42)
6 2.41 (2.17 to 2.67) 1.50 (1.32 to 1.73) 0.37 (0.33 to 0.42)
7 1.93 (1.73 to 2.15) 1.53 (1.34 to 1.75) 0.53 (0.49 to 0.56)
8 1.83 (1.65 to 2.04) 1.39 (1.22 to 1.58) 0.60 (0.56 to 0.65)
9 1.47 (1.31 to 1.64) 1.40 (1.23 to 1.59) 0.73 (0.68 to 0.78)
10 (reference) 1 1 1
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certain community pharmacies will be protected from 
the reduction in funding.22 Initially, community pharma-
cies would not qualify for the scheme if they were located 
within a 1-mile radius of another community pharmacy, 
although we note that, in view of our preliminary work 
around community pharmacy clustering, the formula 
was modified to accommodate community pharmacies 
located in top 20% of deprived areas in England within 
a 0.8-mile radius of another community pharmacy.23 At 
present, however, it is not clear if community pharmacy 
clustering is driven by health need of the local area, or, as 
many community pharmacies are located in urban areas, 
they benefit from the increased footfall by being located 
in these areas. Future work should seek to address this 
important issue. While we are encouraged by the concept 
of the PhAS recognising community pharmacies in 
deprived areas, we believe that future models of funding 
should be based on quality metrics around the provision 
of healthcare and public health services, rather focus on 
distance or clustering of pharmacies. The department 
of health has also recently introduced a quality payment 
scheme whereby extra payments will be paid to community 
pharmacies if certain quality criteria are met. We believe 
this is significant progress, and it is important that this 
concept continue which will remove focus on the number 
of services a community pharmacy undertakes, to that of 
the quality of the service a community pharmacy under-
takes. This approach is critical, given that a recent study 
highlighted that community services are often not related 
to need of the local population, and can be influenced by 
pharmacy ownership type.24 The development of a quality 
metric will help direct funding to community pharmacies 
that are engaged in delivering the higher levels of service.
In terms of the impact on the wider healthcare 
community, previous work shows that if community 
pharmacy services were not present, people would 
use alternate—and more costly—branches of the 
NHS, such as GP and A&E services.3 It is also evident 
that people living in more deprived areas experience 
higher morbidity much earlier in life, compared to 
people living in affluent areas—as represented by lower 
healthy life expectancy.25 A study analysing one million 
GP consultations in London showed that someone aged 
50 years living in the most deprived quintile of English 
neighbourhoods consults with their GP at the same rate 
as someone aged 70 years in the most affluent quin-
tile of neighbourhoods.26 So, community pharmacy 
closures—particularly in deprived areas—are likely to 
increase the workload of general practice. Community 
pharmacies are able to reach people that other services 
cannot. For example, a study has shown that owing to 
their wider accessibility (eg, proximity, opening times, 
no appointment required), many people prefer to 
obtain healthcare from a community pharmacy setting27 
and a qualitative study revealed some people were more 
likely to use a community pharmacy for healthcare 
advice owing to their trusting relationship they develop 
with the pharmacist.28
COnClusIOn
Just over half of community pharmacies in England 
are located in clusters of three or more by 10 min 
walking distance. There is also a positive trend between 
community pharmacy clustering and social deprivation, 
whereby clustering is significantly more common in 
areas of high deprivation. As such, arrangements for 
future community pharmacy funding should not solely 
focus on distance from one pharmacy to another, as 
means of determining funding allocation, as this could 
penalise community pharmacies in our most deprived 
communities, and potentially have a negative effect on 
other healthcare providers, such as GP and A&E services 
by increasing their workload. Future funding models 
of community pharmacy should consider quality of 
healthcare and public health services provided, as well 
as health need of the local area.
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